STOCK TITAN
  1. Home
  2. Sec-filings
  3. DWTX
  4. [EFFECT] Dogwood Therapeutics, Inc. SEC Filing

[EFFECT] Dogwood Therapeutics, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 29, 2026 5:00 P.M.
Form: S-3
CIK: 0001818844
Company Name: Dogwood Therapeutics, Inc.
File Number: 333-292750

Source: View Original Filing on SEC EDGAR

Stock DWTX logo
Dogwood Therapeutics

NASDAQ:DWTX

DWTX Rankings

#5083 Ranked by Market Cap
N/A Ranked by Dividends

DWTX Latest News

Jan 12, 2026
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
Dec 22, 2025
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
Dec 2, 2025
Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045
Nov 11, 2025
Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025
Nov 6, 2025
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

DWTX Latest SEC Filings

Jan 23, 2026
[PRE 14A] Dogwood Therapeutics, Inc. Preliminary Proxy Statement
Jan 20, 2026
[8-K] Dogwood Therapeutics, Inc. Reports Material Event
Jan 13, 2026
[424B5] Dogwood Therapeutics, Inc. Prospectus Supplement (Debt Securities)
Jan 15, 2026
[S-3] Dogwood Therapeutics, Inc. Shelf Registration Statement
Jan 13, 2026
[8-K] Dogwood Therapeutics, Inc. Reports Material Event

DWTX Stock Data

93.04M
7.03M
13.07%
5.92%
1.98%
Biotechnology
Pharmaceutical Preparations
Link
United States
ALPHARETTA